The Dose Makes the Poison: Cannabinoid Hyperemesis Syndrome Goes Mainstream

CME accreditation pending for providers; Certificate of attendance available for both in-person and virtual attendees. This event is FREE. Attend virtually or in person in Seattle, WA (UW Tower Auditorium).

Cannabinoid Hyperemesis Syndrome (CHS) is becoming increasingly visible in clinical settings, but many providers are navigating diagnosis, treatment, and patient communication without clear guidance. 

In a recent survey of Washington State healthcare providers, 70% reported treating patients experiencing severe abdominal pain, persistent nausea, retching, and relentless vomiting associated with heavy cannabis use.  

Patients may not recognize cannabis as the cause of their symptoms, or may be skeptical that CHS exists at all, making effective care even more challenging. 

Join the UW Addictions, Drug & Alcohol Institute (ADAI) on September 18, 2026, for this FREE one-day symposium about: 

-What we know about CHS in Washington State and the U.S.—prevalence in hospitals, emergency departments, and community settings 

-Recognition, diagnosis, treatment, and management across healthcare settings 

-Communicating with patients about a contested diagnosis 

-Policy strategies to reduce CHS and clinical strategies to increase CHS awareness and acceptance

Whether you work in primary care, emergency medicine, behavioral health, nursing, pharmacy, or public health, this symposium will help you better understand, recognize, manage, and communicate about this important cannabis-related health condition.